['diabetes mellitus, type 2']
['empagliflozin medium dose', 'empagliflozin high dose', 'empagliflozin low dose']

        Inclusion criteria:

          -  Children and adolescents with type 2 diabetes mellitus

          -  Insufficient glycaemic control (HbA1c <=10.5%) despite diet and exercise and/or
             metformin and/or stable basal or MDI insulin

          -  Negative for Islet Cell Antigen and Glutamic Acid Decarboxylase autoantibodies and
             fasting C-peptide levels >= 0.85 ng/ml

          -  BMI > 50th percentile for age and sex

        Exclusion criteria:

          -  Uncontrolled hyperglycaemia with a glucose level > 240 mg/dl (> 13.3 mmol/l)

          -  History of acute metabolic decompensation such as diabetic ketoacidosis within 3
             months before the screening visit with the exception of acute de-compensation at the
             time of type 2 diabetes diagnosis

          -  Treatment with weight reduction medications within 4 weeks before randomisation
      